NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

癲癇,自閉症,阿茲海默症,面向其他神經學的狀態遺傳基因檢驗市場

Genetic Testing Markets for Epilepsy, Autism, Alzheimer's and Other Neurologic Conditions

出版商 Kalorama Information 商品編碼 985002
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
癲癇,自閉症,阿茲海默症,面向其他神經學的狀態遺傳基因檢驗市場 Genetic Testing Markets for Epilepsy, Autism, Alzheimer's and Other Neurologic Conditions
出版日期: 2021年01月04日內容資訊: 英文
簡介

遺傳參與神經系統疾病的病因很重要,中樞神經系統疾病 在分類的遺傳性人類疾病中,約佔6400種表型的60%。神經系統疾病,特別是腦部疾病,是醫學發現的最後領域。下一代測序等測試方面的進展有助於確定神經系統疾病的遺傳原因。

神經疾病的遺傳狀態檢驗的領域,與定序等技術的加速重疊,這10年成為大活動領域。神經疾病的認識高漲,高齡化社會的來到,醫療遺傳學的持續性進步,帶動神經疾病遺傳基因檢驗市場的可能性高。

本報告以遺傳性疾病檢驗市場神經學的市場區隔為焦點,提供癲癇、自閉症、阿茲海默症、其他神經學狀態的遺傳基因檢驗市場的相關調查,市場概要,產品,市場規模和預測,各疾病類型的市場分析,COVID-19的影響,主要打入市場企業等資訊。

目錄

第1章 摘要整理

  • 概要
  • 範圍與調查手法
  • 市場概要與可能性
  • COVID-19的影響

第2章 簡介

  • 概要
    • 自閉症
    • 阿茲海默症
    • 其他神經疾病
    • 檢驗類型
    • EXOME序列的限制
    • EXOME定序的成本
    • NGS市場滲透難的領域
    • FISH/ISH所扮演的角色
    • 不排除Denovo突變

第3章 產品和市場潛力

  • 自閉症
  • 阿茲海默症
  • 其他各神經疾病
  • 市場收益與預測

第4章 市場參與企業

  • AMBRY GENETICS
  • ARUP LABORATORIES
  • ASURAGEN
  • ATHENA DIAGNOSTICS, INC.
  • BLUEPRINT GENETICS
  • CENTOGENE AG
  • CYTOX GROUP LIMITED
  • FULGENT GENETICS
  • GENEDX
  • ILLUMINA
  • INVITAE
  • LABORATORY CORPORATION OF AMERICA
  • INEAGEN
  • PERKINELMER, INC.
  • QUEST
  • THERMO FISHER SCIENTIFIC
目錄
Product Code: 21-045

Genetic involvement in the pathogenesis of neurological disease is significant. Central nervous system disorders account for approximately 60 percent of the 6,400 phenotypic entries in cataloged inherited human diseases. Neurological diseases, especially brain diseases, are the last frontier in medical discovery. Advances in testing such as next-generation sequencing have been instrumental in identifying genetic causes for neurological conditions.

The area of inherited condition testing for neurological conditions has become a major area of activity in the last decade or so, coinciding with the acceleration of sequencing and other technologies. Increasing awareness of neurological disorders, the aging population, and continued advancements in medical genetics will likely drive the neurological genetic testing market.

This report “Genetic Testing Markets for Epilepsy, Autism, Alzheimer's and Other Neurologic Conditions ” focuses on the neurological segments of the inherited/ genetic disease testing market, including autism, Alzheimer's disease and other neurological diseases. Next-generation sequencing has provided new abilities in recent years to affordably produce much larger volumes of sequence. It offers the choice of single genes, panels, exomes and other methods.

As part of its coverage, this report provides:

  • Overview of Market
  • Selected Companies and Products in the Neurological Genetic Testing Market
  • Genetic Neurological Testing 2020-2025 (in $ millions)
  • Genetic Testing by Disease Type (Autism, Alzheimer's and other Neurological Diseases) 2020-2025 (in $ millions)
  • COVID-19 Impact
  • Companies in the Market

Company profiled in the report include:

  • Ambry Genetics
  • Arup Laboratories
  • Asuragen
  • Athena Diagnostics
  • Blueprint Genetics
  • Centogene AG
  • Cytox Group Limited
  • Fulgent Genetics
  • Genedx
  • Illumina
  • Invitae
  • Laboratory Corporation of America
  • Lineagen
  • PerkinElmer
  • Quest
  • Thermo Fisher Scientific

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

  • OVERVIEW
  • SCOPE AND METHODOLOGY
  • MARKET OVERVIEW AND POTENTIAL
    • Table 1-1: Genetic Neurological Testing 2020-2025 (in $ millions)
  • COVID-19 IMPACT

CHAPTER 2: INTRODUCTION

  • OVERVIEW
    • Autism
    • Alzheimer's Disease
    • Other Neurological Diseases
    • Types of Testing
    • Limitations in Exome Sequencing
    • Costs of Exome Sequencing
    • Areas of Difficulty for NGS to Penetrate Market
    • Role of FISH/ISH
    • De Novo Mutations Not Excluded

CHAPTER 3: PRODUCTS AND MARKET POTENTIAL

  • GENETIC TESTING FOR AUTISM
  • GENETIC TESTING FOR ALZHEIMER'S DISEASE
  • GENETIC TESTING FOR OTHER SELECT NEUROLOGICAL DISEASES
    • Table 3-1: Selected Companies and Products in the Neurological Genetic Testing Market
  • MARKET REVENUE AND FORECAST
    • Table 3-2: Genetic Neurological Testing 2020-2025 (in $ millions)
    • Table 3-3: Genetic Testing by Disease Type Autism, Alzheimer's and other Neurological Diseases 2020-2025 (in $ millions)

CHAPTER 4: MARKET PARTICIPANTS

  • AMBRY GENETICS
    • Table 4-1: Ambry Genetics Corporate Summary
    • Company Information
  • ARUP LABORATORIES
    • Table 4-2: ARUP Laboratories Corporate Details
    • Company Information
  • ASURAGEN
    • Table 4-3: Asuragen Corporate Summary
    • Company Information
  • ATHENA DIAGNOSTICS, INC.
    • Table 4-4: Athena Diagnostics Corporate Summary
    • Company Information
  • BLUEPRINT GENETICS
    • Table 4-5: Blueprint Genetics Corporate Summary
    • Company Information
  • CENTOGENE AG
    • Table 4-6: Centogene Corporate Summary
    • Company Information
  • CYTOX GROUP LIMITED
    • Table 4-7: Cytox Corporate Summary
    • Company Information
  • FULGENT GENETICS
    • Table 4-8: Fulgent Genetics Corporate Summary
    • Company Information
  • GENEDX
    • Table 4-9: GeneDx Corporate Summary
    • Company Information
  • ILLUMINA
    • Table 4-10: Illumina Corporate Summary
    • Company Information
  • INVITAE
    • Table 4-11: Invitae Corporate Summary
    • Company Information
  • LABORATORY CORPORATION OF AMERICA
    • Table 4-12: LabCorp Corporate Summary
    • Company Information
  • INEAGEN
    • Table 4-13: Lineagen Corporate Summary
    • Company Information
  • PERKINELMER, INC.
    • Table 4-14: PerkinElmer Corporate Summary
    • Company Information
  • QUEST
    • Table 4-15: Quest Corporate Summary
    • Company Information
  • THERMO FISHER SCIENTIFIC
    • Table 4-16: Thermo Fisher Scientific Corporate Summary
    • Company Information